These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
741 related items for PubMed ID: 15003641
21. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U. Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627 [Abstract] [Full Text] [Related]
22. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ. BMJ; 2010 Jun 02; 340():c2509. PubMed ID: 20519267 [Abstract] [Full Text] [Related]
25. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Mangtani P, Roberts JA, Hall AJ, Cutts FT. Int J Epidemiol; 2005 Jun 02; 34(3):565-74. PubMed ID: 15764694 [Abstract] [Full Text] [Related]
27. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Vaccine; 2004 Nov 25; 23(2):132-8. PubMed ID: 15531029 [Abstract] [Full Text] [Related]
28. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR. Pediatrics; 2013 Aug 25; 132(2):e324-32. PubMed ID: 23821695 [Abstract] [Full Text] [Related]
30. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Eur J Health Econ; 2008 Feb 25; 9(1):7-15. PubMed ID: 17333089 [Abstract] [Full Text] [Related]
34. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Castañeda-Orjuela C, Alvis-Guzmán N, Paternina AJ, De la Hoz-Restrepo F. Vaccine; 2011 Oct 13; 29(44):7644-50. PubMed ID: 21854825 [Abstract] [Full Text] [Related]
39. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines]. Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D. Value Health; 2011 Jan 12; 14(5 Suppl 1):S65-70. PubMed ID: 21839902 [Abstract] [Full Text] [Related]